Brigatinib (DrugBank: Brigatinib)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 34 | 神経線維腫症 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04374305 (ClinicalTrials.gov) | June 20, 2020 | 30/4/2020 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 | Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) | Neurofibromatosis Type 2;Vestibular Schwannoma;Non-vestibular Schwannoma;Meningioma;Ependymoma | Drug: Brigatinib | Scott R. Plotkin, MD, PhD | Takeda;The Children's Tumor Foundation | Recruiting | 12 Years | N/A | All | 80 | Phase 2 | United States |